Viatris customer service interviews test whether candidates understand how customer and patient support at a complex generics and off-patent pharmaceutical company differs from retail or technology customer service – where adverse event reports received from patients, caregivers, or healthcare providers must be captured and forwarded to Viatris's pharmacovigilance department within regulatory timelines regardless of whether the caller's primary intent is to report a product quality issue or request patient assistance, where medical information specialists handling healthcare provider inquiries about Viatris products must provide scientifically accurate information consistent with FDA-approved labeling without making promotional claims or providing off-label information that would constitute illegal drug promotion, and where patient assistance program coordinators helping uninsured or underinsured patients access EpiPen or other Viatris branded products must navigate insurance benefit verification, prior authorization support, and income-based eligibility criteria to connect patients with appropriate access programs. Customer service at Viatris spans pharmacovigilance-integrated adverse event handling (where every customer-facing team member is a potential first point of contact for adverse event and product quality complaint information, and where the regulatory obligation to collect, document, and forward reportable information to the pharmacovigilance function within defined timelines applies regardless of whether the conversation's primary purpose was a billing question or a patient assistance inquiry), medical information services for healthcare providers (where pharmacists, physicians, nurses, and other HCPs contact Viatris's medical information line with questions about approved indications, dosing, drug interactions, and product characteristics that medical information specialists must answer using only FDA-approved labeling information without promoting products for unapproved uses), patient access program coordination (where Viatris's patient assistance programs for EpiPen and other branded products help patients who lack adequate insurance coverage to access medications through income-based free product programs, commercial insurance copay assistance, or appeals support for denied prior authorizations), and product quality complaint triage and investigation coordination (where customers who report product quality issues including device malfunctions, unusual appearance, or packaging defects trigger investigations under FDA's quality complaint handling regulations that require Viatris to assess whether the reported issue constitutes a mandatory adverse event report or recall consideration).
Start your free Viatris Customer Service practice session.
What interviewers actually evaluate
Pharmacovigilance Integration, Medical Information Compliance, and Patient Access Navigation
Viatris customer service interviews probe whether candidates understand how pharmaceutical customer support differs from commercial customer service in the adverse event regulatory obligation (an FDA-registered pharmaceutical manufacturer must report serious unexpected adverse events to FDA within 15 calendar days of first receiving information about the event, and expedited adverse event reports for labeled serious adverse events within the 15-day window – creating a customer service obligation that applies regardless of the channel through which the information arrives, and where a customer service representative who fails to capture and forward adverse event information received during a patient assistance call creates regulatory noncompliance that Viatris's pharmacovigilance function cannot retroactively cure), the medical information fair balance and off-label restriction (medical information specialists who answer HCP questions about Viatris products operate under FDA's prohibition on off-label promotion – where an HCP asking about dosing of EpiPen in pediatric patients below the labeled weight threshold is asking about an off-label use that the medical information specialist cannot proactively recommend, but can provide the scientific literature information that supports the HCP's independent clinical judgment when the HCP specifically requests it), and the patient assistance program eligibility complexity (Viatris's EpiPen patient assistance programs have income eligibility thresholds, insurance status requirements, and enrollment processes that patient access coordinators must navigate accurately to prevent patients who qualify for assistance from being incorrectly denied or patients who do not qualify from receiving assistance in ways that create program fraud risk).
The product quality complaint regulatory dimension creates a customer service obligation that consumer product companies do not share: when a patient reports that their EpiPen failed to deploy properly during an emergency, the customer service representative must simultaneously manage the immediate patient welfare concern, capture complete product lot number and usage information for the quality investigation, determine whether the reported failure constitutes a serious adverse event requiring pharmacovigilance notification, and initiate the quality complaint investigation process – all within the interaction where the patient may be emotionally distressed from the emergency situation that preceded the call.
What gets scored in every session
Specific, sentence-level feedback.
| Dimension | What it measures | How to answer |
|---|---|---|
| Adverse event recognition and pharmacovigilance routing | Do you understand how to recognize and appropriately handle adverse event information received during any customer interaction – what constitutes a reportable adverse event versus a product quality complaint versus a general product inquiry, how to capture the minimum required information including patient identifier, reporter information, product information, and adverse event description when a caller provides incomplete information and may be reluctant to share personal details, and how to transition a customer service interaction that began as a patient assistance inquiry into an adverse event data collection workflow without alarming the caller or prematurely ending the productive conversation? We flag customer service answers that treat adverse event reporting as a separate pharmacovigilance function rather than a customer service obligation that applies in every interaction where reportable information is received. | Reportable vs. non-reportable event distinction, minimum data element collection, interaction transition protocol |
| Medical information services within FDA off-label promotion restrictions | Can you describe how to manage medical information service for healthcare providers within the boundaries of FDA's approved labeling and off-label promotion prohibitions – how to respond when a physician asks for information about EpiPen dosing in a pediatric patient whose weight is below the labeled threshold, what the distinction is between proactively providing off-label information (prohibited promotional activity) versus providing scientific literature in response to a specific unsolicited request from an HCP (generally permissible), and how to ensure that the medical information response provides the scientific accuracy the HCP needs for clinical decision-making without constituting a promotional claim for an unapproved use? We score whether your medical information approach engages with the FDA regulatory boundary between permissible scientific exchange and prohibited off-label promotion that applies specifically to pharmaceutical manufacturer medical information functions. | Off-label promotion prohibition boundary, unsolicited request scientific exchange, labeled vs. unlabeled dosing inquiry |
| EpiPen patient assistance program coordination and access navigation | Do you understand how to coordinate patient access to Viatris's EpiPen patient assistance programs – how to assess a patient's eligibility for income-based free product programs versus commercial insurance copay assistance based on their insurance status and income information, what the prior authorization support services include for patients whose commercial insurance requires PA for EpiPen, and how to manage the situation where a patient in an emergency situation needs access to EpiPen before the standard assistance program enrollment process can be completed? We detect customer service answers that treat patient assistance as a standard enrollment form completion without engaging with the insurance benefit verification, prior authorization support, and emergency access pathways that make pharmaceutical patient assistance programs operationally complex. | Eligibility assessment for free product vs. copay assistance, PA support for commercial insurance, emergency access pathway |
| Product quality complaint triage and FDA regulatory reporting assessment | Can you describe how to handle a patient call reporting that their EpiPen failed to deploy during an anaphylactic episode – how to assess whether the reported device malfunction constitutes an adverse event reportable under FDA's expedited safety reporting requirements versus a product quality complaint requiring investigation under quality system procedures, what information must be collected from the patient for both the adverse event report and the quality investigation, and how to coordinate the dual pharmacovigilance and quality complaint workflows in a way that completes the regulatory data collection while providing the patient with appropriate follow-up about the investigation? We flag customer service answers that treat a device malfunction during emergency use as only a quality complaint without engaging with the adverse event assessment that device failure during clinical use requires under FDA's medwatch reporting regulations. | Device failure adverse event versus quality complaint assessment, dual workflow data collection, patient follow-up coordination |
How a session works
Step 1: Choose a Viatris customer service scenario – adverse event recognition and pharmacovigilance data collection, medical information services for healthcare providers within FDA promotional restrictions, EpiPen patient assistance program coordination and access navigation, or product quality complaint triage and FDA regulatory reporting assessment.
Step 2: The AI interviewer asks realistic Viatris-style questions: how you would handle a call from a patient who is calling to request enrollment in Viatris's EpiPen patient assistance program and mentions during the enrollment conversation that their child had a severe allergic reaction last week, used the EpiPen they had on hand, and the injection seemed to hurt more than they expected and the reaction took longer than normal to resolve – including how you would assess whether the information about the EpiPen use and the extended reaction constitutes a reportable adverse event, what minimum information you must collect from the patient about the event before ending the call, and how to transition back to completing the patient assistance enrollment after collecting the required adverse event information; how you would respond to a physician calling Viatris's medical information line asking for information about the use of Celebrex in patients with sulfonamide allergy – because celecoxib contains a sulfonyl group and the physician has heard that some references cite a cross-reactivity concern with sulfonamides while the current label does not include a contraindication – including what the distinction is between a proactive promotional response and a response to a specific clinical inquiry, what scientific literature Viatris's medical information function can provide about the sulfonamide cross-reactivity question, and how to document the inquiry and response in Viatris's medical information tracking system; or how you would support a patient who calls because their commercial health plan denied prior authorization for Yupelri citing that COPD patients must fail a standard metered-dose inhaler LAMA therapy before nebulized LAMA treatment is approved – including what the appeal process options are, what clinical documentation the prescribing pulmonologist should include in a peer-to-peer appeal to address the plan's criteria, and what alternative access pathways Viatris's patient support hub can offer during the appeal period.
Step 3: You respond as you would in the actual interview. The system scores your answer on adverse event handling, medical information compliance, patient assistance coordination, and quality complaint triage.
Step 4: You get sentence-level feedback on what demonstrated genuine pharmaceutical customer service expertise and what needs stronger pharmacovigilance obligation specificity or medical information compliance analysis.
Frequently Asked Questions
What are pharmaceutical adverse event reporting obligations and how do they affect customer service?
FDA regulations require manufacturers to report adverse events – unexpected harmful patient outcomes associated with drug use – through a tiered reporting system based on severity and expectedness. Serious unexpected adverse events must be reported within 15 calendar days of the manufacturer first receiving the information, regardless of the channel through which the information arrived. This means that when a patient calls Viatris's customer service line for any reason and mentions a product-associated health outcome, the representative is a potential first point of contact for reportable safety information. Customer service teams must be trained to recognize reportable information, collect minimum required data elements, and forward the information to the pharmacovigilance function within timelines that preserve FDA's 15-day reporting window. The obligation applies to safety information received through any customer service channel including phone, email, patient support websites, and social media monitoring.
What restrictions apply to Viatris's medical information function?
FDA's prohibition on off-label drug promotion applies to pharmaceutical manufacturer medical information services, restricting medical information specialists from proactively providing information about uses, doses, or patient populations not described in a product's approved FDA labeling. Medical information specialists can respond to unsolicited requests from healthcare providers for scientific information about off-label uses by providing published clinical data without making promotional claims about the off-label use's safety or efficacy. The distinction between a prohibited promotional response and a permissible scientific exchange depends on whether the request was genuinely initiated by the HCP or was triggered by promotional activities, and on whether the information provided is presented as scientific data rather than as a manufacturer recommendation. Medical information responses must also include fair balance regarding the product's risks and limitations consistent with the approved labeling.
What patient assistance programs does Viatris offer for EpiPen?
Viatris has offered multiple patient assistance pathways for EpiPen patients who face access challenges due to insurance coverage gaps or cost-sharing burdens. Free product programs have historically been available for uninsured and underinsured patients below income thresholds, and Viatris introduced a generic version of EpiPen at a lower list price to provide a lower-cost option for patients who cannot afford the branded product. Copay assistance programs for patients with commercial insurance reduce out-of-pocket costs for eligible patients. The availability, eligibility requirements, and program terms of patient assistance programs change over time as Viatris revises access strategy, and patient access coordinators must be current on the specific program terms at the time of patient enrollment rather than relying on historical program descriptions.
How does Viatris handle product quality complaints about EpiPen?
EpiPen product quality complaints including reports of device malfunction, delivery failure, unusual product appearance, or packaging defects trigger quality investigations under Viatris's FDA-required quality system procedures. Because EpiPen is a combination product with both a drug component and a device component, quality complaints are subject to both pharmaceutical quality system regulations under 21 CFR Part 211 and medical device quality system regulations. When a customer reports a product quality issue, Viatris customer service must collect the product lot number, expiration date, storage conditions, and description of the quality issue to support the investigation. Quality complaints that involve patient harm or device failure during emergency use may also constitute adverse events requiring pharmacovigilance reporting alongside the quality investigation – creating a dual-track response obligation.
How has the Viatris formation from Mylan and Pfizer Upjohn affected customer service?
The November 2020 combination of Mylan N.V. and Pfizer's Upjohn division created Viatris as a new company with customer service responsibilities spanning Mylan's legacy generic portfolio and patient assistance programs alongside Upjohn's branded off-patent products including Celebrex, Norvasc, and Lyrica in international markets. The combination required integrating customer service systems, patient assistance program platforms, and medical information knowledge bases from two very different pharmaceutical businesses – Mylan's generic-focused model and Upjohn's branded product approach. From the customer perspective, callers who had existing relationships with Mylan's patient support teams or Pfizer's medical information services encountered new Viatris branding and potentially new contact information and service processes during the integration period.
Also practice
One full session free. No account required. Real, specific feedback.
